Navigation Links
Newer 'Second-Line' Diabetes Drug May Outperform Older Meds
Date:6/28/2012

THURSDAY, June 28 (HealthDay News) -- A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates.

Researchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.

Patients with type 2 diabetes may stop responding to metformin over time. Others who do not respond to metformin alone are given a second drug to help them maintain normal blood sugar levels. The researchers noted that which drug they should be prescribed is unclear.

The researchers pointed out that most patients are prescribed a class of drugs called sulphonylureas to supplement metformin. However, these drugs can sometimes lead to hypoglycemia and weight gain, which increases the patients' risk for heart attack and stroke.

To compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years. The study, which was funded by linagliptin's maker, Boehringer Ingelheim, involved 1,500 people from 16 countries with type 2 diabetes. None of the patients had responded to metformin alone.

Although the effectiveness of the drugs were similar, the study showed the side effects of linagliptin were much less severe than those of glimepiride. The researchers found that 7 percent of patients on linagliptin experienced hypoglycemia, compared to 38 percent of patients treated with glimepiride.

The patients on linagliptin also had fewer heart attacks and strokes compared to those being treated with glimepiride.

The researchers argued that since linagliptin allows the body to increase the amount of insulin it produces in a glucose-dependent way, the risk for hypoglycemia may be significantly lower.

And since hypoglycemia "can have substantial negative clinical consequences" in terms of risk for death, illness, mental function and poor quality of life, preventing it is crucial, study co-author Baptist Gallwitz, of Tubingen University Hospital, said in a news release.

The study authors pointed out linagliptin was licensed in 2011 and this is the first long-term study examining its safety and effectiveness. They added more research is needed to confirm their findings.

One expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.

The new study provides more evidence that drugs like linagliptin "are just as good as the old standby sulfonylurea therapies, with the added benefits of inducing fewer hypoglycemic events, causing less weight gain, along with a likely decrease in cardiovascular events," said Dr. Stuart Weiss, an endocrinologist at NYU Langone Medical Center and clinical assistant professor at the NYU School of Medicine, New York City.

But millions of Americans suffer from type 2 diabetes, so "cost issues favoring sulfonylureas may be the only reason for preferring continued sulfonylurea use," he added. The results of a larger, ongoing study currently underway may help resolve the issue of whether the newer drug is worth the extra money, Weiss said.

The study was published online June 27 in The Lancet.

More information

The American Diabetes Association provides more information on type 2 diabetes.

-- Mary Elizabeth Dallas

SOURCE: Stuart Weiss, M.D., endocrinologist, NYU Langone Medical Center, and clinical assistant professor, NYU School of Medicine, New York City; The Lancet, news release, June 27, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Antidepressants May Be Safe for Parkinsons Patients
2. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
3. UT Southwestern study shows treating diabetes early, intensively is best strategy
4. NIH, DOD grants to fund prostate cancer, diabetes research at UH
5. Metformin may lower cancer risk in people with Type 2 diabetes
6. Secondhand Smoke Linked to Raised Diabetes Risk
7. Metformin Outperforms Common Class of Diabetes Drugs in Study
8. Diabetes Can Make a Comeback After Weight-Loss Surgery: Study
9. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
10. Preventing or better managing diabetes may prevent cognitive decline, according to UCSF study
11. Weight-Loss Surgery May Improve Diabetes-Related Kidney Damage
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer 'Second-Line' Diabetes Drug May Outperform Older Meds
(Date:1/20/2017)... ... ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are fully ... - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 lens ... and light leak transitions have a very high-dynamic range for super smooth falloff. Simply ...
(Date:1/20/2017)... ... 2017 , ... “The Angel”: a heartwarming and earnest tale of faith ... his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former ... impassioned writer. , When asked of her new book, Marjorie says, “‘The Angel’ was ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... ... is God’s Lighthouse”: a moving and colorful collection of prayers that reminds readers ... author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published works ... school and have many different titles,” Gaapf mentions about his different works. “I am ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare & Medicaid Services ... Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid for ... part of the Administration’s effort to build a system that delivers better care and ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017 Conference Call and Webcast to Follow ... today announced it will release results for the fourth quarter of ... ... a conference call at 4:30 PM ET on Wednesday, February 15, ... year 2016 financial results and other corporate activities. To participate in ...
(Date:1/19/2017)... N.J. , Jan. 19, 2017 Many ... $100 for their medication when a pharmacy just a ... exact prescription.  To alleviate this problem Medicationdiscountcard.com ... patients to see exactly how much their medication will ... Shopping Made Easy ...
(Date:1/19/2017)... , January 19, 2017 According to ... for cryotherapy is set to witness a CAGR of 6.5% during ... America will continue to be the leading market for ... ... Suppliers are emphasizing on ensuring affordable and adequate supply of gas ...
Breaking Medicine Technology: